Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
NEW HAVEN, Conn., April 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today provided an update regarding the impact of the COVID-19 pandemic on its overall business continuity, including clinical trials, supply chain, and discovery research. Throughout the ongoing COVID-19 pandemic, Arvinas remains committed to keeping employees and their families safe and to reduce the number of people exposed to the virus. Arvinas also remains committed to continuing to create a new class of drugs based on targeted protein degradation, including continued development of the company’s PROTAC® protein degraders currently in ongoing clinical trials. In early March 2020, Arvinas activated business continuity plans to minimize business disruption and ensure employee well-being. Arvinas continues to expect planned clinical data releases for ARV-110 or ARV-471. Nonetheless, the compa
Show less
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Arvinas to Present at Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)GlobeNewswire
- Revisiting the Narrative for Arvinas as Analyst Views Shift with New Pipeline and Partner Risks [Yahoo! Finance]Yahoo! Finance
- Arvinas (NASDAQ:ARVN) had its price target raised by analysts at Stephens from $14.00 to $15.00. They now have an "overweight" rating on the stock.MarketBeat
ARVN
Earnings
- 11/5/25 - Beat
ARVN
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/7/25 - Form 4
- ARVN's page on the SEC website